Advancing a True Stand-Apart in the Competitive Field of Immuno-Oncology
Our lead asset, imneskibart (AU-007), is a potential best-in-class, wholly owned investigational antibody that is unlike any other IL-2 therapeutic. Allow us to explain why.
A distinctly different approach in IO
Imneskibart is a human monoclonal antibody with drug-like properties that provides advantages over non-natural biologics and that was designed with the assistance of artificial intelligence. Monoclonal antibodies are known for their developability as well as their ease of manufacturing and administration.
With imneskibart, Aulos™ is advancing clinical development of a novel therapeutic that is different from all other IL-2 therapeutics currently in development – it binds to the portion of IL-2 that interacts with the CD25 receptor subunit, preventing regulatory T cell expansion that can lead to immune activation while allowing IL-2 to bind to CD8 effector T cells, which expands CD8 effector T cells and drives tumor killing. Read more about how Aulos stands out in the field in Nature Biotechnology.
Imneskibart Delivers Outstanding Phase 2 Activity in CPI-Refractory Melanoma and Adenocarcinoma NSCLC
Aulos Bioscience presented positive Phase 2 data from its imneskibart study at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, held November 4-8, 2026, in Phoenix, Arizona. The results demonstrated remarkable activity with imneskibart-based regimens in heavily pretreated, CPI-refractory melanoma and adenocarcinoma non-small cell lung cancer (NSCLC), comparing favorably with historical treatment benchmarks.
Across the melanoma and NSCLC cohorts, pharmacodynamic findings continue to support imneskibart’s differentiated mechanism of redirecting IL-2 toward immune effector cells and away from immunosuppressive regulatory T cells. Imneskibart-based regimens also continue to demonstrate manageable safety profiles, with most drug-related adverse events reported as Grade 1 or 2, no capillary leak syndrome or treatment-related deaths, and no new toxicity signals observed.
View Abstracts and Publications for key findings presented at SITC.
CPI-Refractory Adenocarcinoma NSCLC
In advanced adenocarcinoma NSCLC, the triplet regimen of imneskibart plus low-dose, subcutaneous aldesleukin and avelumab achieved a median progression-free survival (PFS) of 5.8 months, a confirmed objective response rate (ORR) of 21% and a disease control rate (DCR) of 86%. Patients had received a mean of 2.6 prior lines of therapy. Median overall survival had not been reached at a median follow-up of 10.6 months.
Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: Phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)
Doublet CPI-Refractory Melanoma
In melanoma, the triplet regimen of imneskibart plus low-dose, subcutaneous aldesleukin and nivolumab achieved a median PFS of 9.1 months and a 28% ORR, including one confirmed complete response. The imneskibart doublet regimen without nivolumab achieved a median PFS of 6.9 months and a 29% ORR, including a confirmed complete response lasting more than 32 months. Patients had received a mean of 2.7 and 2.4 prior lines of therapy in the triplet and doublet cohorts, respectively.
Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing Phase 1/2 study
Imneskibart has been rigorously evaluated for safety and preclinical efficacy. Numerous preclinical studies have shown that imneskibart tips the delicate balance toward immune activation (CD8+ effector T cell, NK cell and NKT cell activity) and away from immune suppression (regulatory T cell activity). In in vivo studies, imneskibart treatment results in tumor growth inhibition in animal models resistant to immune checkpoint inhibitors. Additional study findings show that imneskibart exhibits favorable pharmacokinetic (PK) properties and a long serum half-life for improved dosing regimens.
Aulos has advanced imneskibart to the Phase 2 portion of its Phase 1/2 clinical trial following demonstration in Phase 1 of a well-tolerated safety profile and early anti-tumor activity in heavily pre-treated patients with unresectable locally advanced or metastatic solid tumor cancers. Expansion cohorts are focusing on melanoma and non-small cell lung cancer (NSCLC).
Aulos Expanded Access Policy
Aulos development resources are focused on conducting clinical studies required by regulatory authorities to fully answer important scientific questions about the potential risks and benefits of imneskibart, and to obtain regulatory approval.
Due to limited resources, imneskibart expanded access is currently not available to patients outside of clinical trial participation and post-trial access.
Patient Eligibility Criteria
To be eligible for post-trial access to imneskibart, patients must meet the following criteria:
- Participated in study CP-AU-007-01.
- Continues to benefit from and tolerate treatment with imneskibart.
- In the medical judgment of the treating Investigator, will continue to obtain benefit from imneskibart post-trial access.
Investigational Product Criteria
Imneskibart will be made available to eligible patients upon approval of an Expanded Access Request.
Treating Physician Criteria and Responsibilities
The physician(s) attending to the patient(s) who is/are receiving an investigational product through expanded access participated in study CP-AU-007-01 and is/are properly licensed and fully qualified to administer the product. The physician must agree in writing to comply with:
- Any applicable country-specific legal and regulatory requirements related to providing an investigational product under expanded access.
- Any Aulos Bioscience requirements in terms of medical criteria, safety reporting, drug supply/use and protection of intellectual property.
Requests for Post-Trial Access
A treating physician may submit questions or requests regarding expanded access to Aulos General inquiries at info@aulosbio.com.

